Entering text into the input field will update the search result below

Rhythm stock rises 9% as obesity therapy setmelanotide helps reduce BMI in mid-stage study

Jul. 12, 2022 8:05 AM ETRhythm Pharmaceuticals, Inc. (RYTM)By: Ravikash, SA News Editor

A asian men measures his fat belly with a measuring tape on a plain background

Deepak Verma/iStock via Getty Images

Rhythm Pharmaceuticals (NASDAQ:RYTM) said its medicine setmelanotide helped reduce Body Mass Index (BMI) in patients with severe obesity and hyperphagia (excessive hunger) in people living with hypothalamic obesity as per interim data from a phase 2 trial.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.